Review highlights emerging therapies and improvements in metabolic dysfunction-associated steatohepatitis, suggesting significant advancements in treatment.
Key Points
The central question focuses on the evaluation of new therapeutic options for metabolic dysfunction-associated steatohepatitis (MASH).
Review of existing literature on pharmacologic, bariatric, and endoscopic interventions for MASH.
Integration of data on emerging therapies and their effectiveness.
Highlighting the potential benefits of various interventions for MASH.
Discussion on the need for focusing beyond histologic improvement in therapy evaluation.